Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 230
- Registration Number
- NCT01718873
- Locations
- 🇮🇹
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Radiation: RadiotherapyProcedure: HyperthermiaDrug: 5-FluorouracilDrug: CapecitabineDrug: Oxaliplatin
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 59
- Registration Number
- NCT01716949
- Locations
- 🇩🇪
LMU München, Campus Großhadern, Medizinische Klinik III, Hyperthermie, München, Germany
🇩🇪Klinik Bad Trissl, Innere Medizin, Bad Trissl, Germany
🇩🇪Schlossbergklinik, Oberstaufen, Germany
Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- xie congying
- Target Recruit Count
- 208
- Registration Number
- NCT01711242
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
- Conditions
- Gastro Oesophageal Cancer
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 35
- Registration Number
- NCT01710592
- Locations
- 🇮🇪
Mercy University Hospital, Cork, Ireland
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇪Mater Misericordiae University hospital & Mater Private Hospital, Dublin, Ireland
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
- Conditions
- Metastatic Colorectal Cancer (mCRC)CancerSolid Tumor
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Lipomedix Pharmaceuticals Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT01705002
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇮🇱Chaim Sheba Medical center, Ramat Gan, Israel
🇮🇱Rambam Health Care Campus, Haifa, Israel
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: capecitabineDrug: celecoxibOther: pharmacological studyOther: laboratory biomarker analysisOther: pharmacogenomic studies
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 21
- Registration Number
- NCT01705106
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
- Conditions
- Breast CancerGastric Cancer
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT01702558
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, PR, Brazil
🇧🇷Instituto Oncologico de Ribeirao Preto - INORP, Ribeirao Preto, SP, Brazil
🇧🇷Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*, Sao Jose do Rio Preto, SP, Brazil
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT01697072
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 882
- Registration Number
- NCT01696695
- Locations
- 🇭🇺
Josa Andras Korhaz; Dept of Oncoradiology, Nyíregyháza, Hungary
🇭🇺Zala megyei Önkormányzat Kórház és Rendelõintézet, Zalaegerszeg, Hungary
🇭🇺Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 10
- Registration Number
- NCT01677884
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, Val de Marne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.